%D8%B1%D9%88%D9%83%D8%B3%D9%88%D9%84%D9%8A%D8%AA%D9%8A%D9%86%D9%8A%D8%A8Category:RuxolitinibRuxolitinibRuxolitinib%D8%B1%D9%88%DA%A9%D8%B3%D9%88%D9%84%DB%8C%D8%AA%DB%8C%D9%86%DB%8C%D8%A8RuxolitinibRuxolitinib%E3%83%AB%E3%82%AD%E3%82%BD%E3%83%AA%E3%83%81%E3%83%8B%E3%83%96RuksolitinibasRuksolitinibRuksolitinibQ7383611
about
P3781
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibLong-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsKinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.New generation small-molecule inhibitors in myeloproliferative neoplasms.Ruxolitinib for the treatment of myelofibrosis: its clinical potential.Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers
P921
Q1194520-DFF7275C-45E4-4B6E-BFA6-21E5B5C8ED31Q1368780-CB20EA45-E195-4794-8965-B46522B9D566Q1542410-EC90227C-AA01-481E-B72E-72FB80EB2D76Q1752571-AC75C99D-D1FA-4B9D-869B-5E4D2F3810ACQ1963588-CD36FB45-7405-4CDC-94F9-0B70367C6465Q264118-265608A6-B3BD-42A9-AE29-42A303104CFAQ29496-B9E5B714-5F14-483E-9DCE-4FF17B36620EQ585285-769A4D90-A4D9-4928-8FA4-43E23C499CE3Q84263196-342ab52d-40de-0f52-cff0-f726685d6624Q933716-B3234887-227E-4C70-BF59-610AFD9189F3Q948318-DC7DA33A-9E78-45E1-95D7-84DD843EFC61Q954625-4FA11FFB-BC3C-4335-B140-87CE017188F9
P2176
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Ruksolitinib
@sh
Ruksolitinib
@sr
Ruksolitinibas
@lt
Ruxolitinib
@de
Ruxolitinib
@en-ca
Ruxolitinib
@en-gb
Ruxolitinib
@it
ruksolitinib
@hr
ruksolitinib
@nn
ruxolitinib
@ca
type
label
Ruksolitinib
@sh
Ruksolitinib
@sr
Ruksolitinibas
@lt
Ruxolitinib
@de
Ruxolitinib
@en-ca
Ruxolitinib
@en-gb
Ruxolitinib
@it
ruksolitinib
@hr
ruksolitinib
@nn
ruxolitinib
@ca
altLabel
(R)-ruxolitinib
@en
INC424
@en
INCB 18424
@en
INCB018424
@en
INCB424
@en
Jakafi®
@en
Jakavi
@en
Jakavi®
@en
Ruxolitinib
@en
鲁索替尼
@zh
prefLabel
Ruksolitinib
@sh
Ruksolitinib
@sr
Ruksolitinibas
@lt
Ruxolitinib
@de
Ruxolitinib
@en-ca
Ruxolitinib
@en-gb
Ruxolitinib
@it
ruksolitinib
@hr
ruksolitinib
@nn
ruxolitinib
@ca